JAC Advance Access published online on August 5, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl315
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Antibiotic Resistance Monitoring and Reference Laboratory, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
* To whom correspondence should be addressed. Objectives: Fosfomycin is a possible oral treatment for lower urinary tract infections caused by Escherichia coli with CTX-M extended-spectrum Methods: Urinary E. coli isolates with CTX-M Results: The disc screen identified 10 likely mutators and quantitative tests indicated that 9 of these had mutation frequencies of 8.0 x 10-6-1.5 x 10-4 for fosfomycin and 0.1-2.3 x 10-6 for rifampicin. These mutators were diverse in terms of PFGE type and 4 of the 10 were confirmed as strong mutators with rifampicin and fosfomycin. Only the strongest mutator isolate and hypermutable MutS- control strain consistently gave single-step mutants resistant to 256 mg/L fosfomycin. No nitrofurantoin-resistant mutants were selected from any isolate, although they could be selected from the hypermutable MutS- control strain. Conclusions: Mutator phenotypes were found among E. coli expressing CTX-M
Received May 10, 2006
Revised July 7, 2006
Accepted July 12, 2006
Brief report
Mutators among CTX-M
Matthew J. Ellington 1 *, David M. Livermore 1, Tyrone L. Pitt 2, Lucinda M. C. Hall 3, and Neil Woodford 1
-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance
2 Laboratory of Health Care Associated Infection, Centre for Infections, Health Protection Agency, London, UK
3 Barts and The London School of Medicine and Dentistry, London, UK
Matthew J. Ellington, E-mail: matthew.ellington{at}hpa.org.uk
Abstract 
-lactamases but is vulnerable to mutational resistance. Hypermutability among natural E. coli populations might facilitate the emergence of resistance to fosfomycin. We therefore examined the prevalence of mutators amongst urinary isolates of E. coli producing CTX-M -lactamases.-lactamases (n = 220) were screened for resistance to both rifampicin and fosfomycin, as well as a mutator phenotype, by rifampicin and fosfomycin disc assays. Mutation frequencies for 10 isolates, identified as mutators by the initial disc screen, were determined in triplicate on agar with rifampicin or fosfomycin at 4x MIC and with fosfomycin or nitrofurantoin at 256 mg/L.-lactamases and were independent of strain type. These had an increased propensity to fosfomycin resistance.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. J. Knottnerus, S. Nys, G. ter Riet, G. Donker, S. E. Geerlings, and E. Stobberingh Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? J. Antimicrob. Chemother., August 1, 2008; 62(2): 356 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Stepanova, M. Pimkin, A. A. Nikulin, V. K. Kozyreva, E. D. Agapova, and M. V. Edelstein Convergent In Vivo and In Vitro Selection of Ceftazidime Resistance Mutations at Position 167 of CTX-M-3 {beta}-Lactamase in Hypermutable Escherichia coli Strains Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1297 - 1301. [Abstract] [Full Text] [PDF]
|
|